[EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].

CONCLUSIONS: The neurologist should be aware of current evidence to assess the risk-benefit of starting, maintaining and stopping disease-modifying therapies in multiple sclerosis during the pandemic. PMID: 32329046 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32329046?dopt=Abstract

Source: Revista de Neurologia - April 26, 2020 Category: Neurology Authors: Costa-Frossard L, Moreno-Torres I, Meca-Lallana V, García-Domínguez JM, En Representación Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autónoma de Madrid ERDGEEDCAM Tags: Rev Neurol Source Type: research